- Tytuł:
- Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
- Autorzy:
- Źródło:
- American Journal of Hematology; Apr2024, Vol. 99 Issue 4, p774-779, 6p
Czasopismo naukowe